Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Trial Identifier:	3475-204
Sponsor:	MSD
Start Date:	May 2016
Primary Completion Date:	January 2026
Study Completion Date:	January 2026
Condition:	Hodgkin's lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.